Tert-Butyl (2R)-2-(Aminomethyl)Pyrrolidine-1-Carboxylate

In the preparation of chiral vicinal diamine ligands for asymmetric transfer hydrogenation, tert-Butyl (2R)-2-(aminomethyl)pyrrolidine-1-carboxylate is first subjected to controlled Boc removal using trifluoroacetic acid in dichloromethane (1:1 v/v) at 0–5 °C over 2 hours. The resulting (R)-2-(aminomethyl)pyrrolidine bis-TFA salt is neutralised with aqueous NaOH and extracted into dichloromethane; this solution must be dried to a water content below 50 ppm (Karl Fischer titration) before condensation with picolinaldehyde and subsequent reduction with 2.0 eq NaBH₄ to afford the unsymmetrical diamine ligand. For complexation, 1.1 eq of the ligand is reacted with [RuCl₂(p-cymene)]₂ in anhydrous isopropanol inside an argon-atmosphere glovebox (O₂ < 1 ppm). The preformed catalyst solution is introduced at a substrate-to-metal ratio (S/C) of 200:1 to the ketone substrate, with 0.5 M isopropanol serving as hydrogen donor and solvent at 60 °C. Production-scale equipment includes a Hastelloy C-22 stirred reactor equipped with a vapour-phase condenser, an in-line FTIR probe for real-time reaction monitoring, and a simulated moving-bed chromatography system with a Chiralpak IA column (20 µm particle size) for enantiomeric separation. Addition of the ligand slightly above stoichiometry (1.05–1.2 eq relative to the Ru dimer) prevents catalyst precipitation during transfer hydrogenation; however, a molar excess beyond 1.3 eq leads to formation of an inactive bis-ligand complex that reduces turnover frequency by up to 40%. The resulting chiral alcohol products—typically (R)-1-phenylethanol or (S)-1-(2-naphthyl)ethanol—exceed 98% ee and find downstream use as fragrance intermediates and chiral dopants for ferroelectric liquid crystals. Regulatory compliance for ligand manufacturing follows ISO 9001:2015 standards; residual solvents are controlled to ICH Q3C limits, and elemental impurities adhere to ICH Q3D Class 1 and 2A limits, with ruthenium content held below 10 µg/g in the final isolated product. Thermal stability of the Boc-protected precursor requires storage at −20 °C; prolonged exposure to ambient moisture induces gradual deprotection and dimerisation through carbamic anhydride formation, a degradation pathway detectable by HPLC-MS at a mass increase of 44 Da.

What Are the Critical Parameters for Preserving Optical Enantiomeric Excess During N-Boc Deprotection?

The conversion of the N-Boc-protected aminomethylpyrrolidine to its free base constitutes a pivotal operation in the synthesis of small-molecule drug candidates because the centre at the 2-position is susceptible to epimerisation when exposed to strong acid at elevated temperature. Batchwise deprotection with 4 M HCl in 1,4-dioxane (3 vol) at 0–5 °C over 2 h routinely retains >99% ee if the internal temperature is prevented from exceeding 5 °C; excursions above 25 °C for more than 15 minutes decrease enantiopurity by 3–5% as determined by chiral HPLC on a Chiralpak AD-H column (mobile phase: hexane/ethanol/diethylamine 90/10/0.1). In continuous-flow processes, a Corning Advanced-Flow Reactor G1 SiC module enables residence times of 60 seconds and heat-transfer coefficients of 1700 W·m⁻²·K⁻¹, limiting the thermal stress and delivering the free amine hydrochloride with an ee loss below 0.2%. After isolation, the amine is typically coupled to a carboxylic acid fragment in dimethylformamide using 1.05–1.20 eq HATU and 2.5 eq N,N-diisopropylethylamine at 15–20 °C. When the free base is generated in situ without full removal of excess acid, formation of the corresponding pyrrolidinium salt prior to coupling can suppress racemisation; however, residual water from neutralisation must be stripped to ≤500 ppm to avoid HATU decomposition. The amide coupling itself proceeds with a reaction volume productivity of 12 kg API·m⁻³·day⁻¹ in a pilot-scale GMP suite adhering to ICH Q7 guidelines for active pharmaceutical ingredients. For early-stage campaigns, the starting-material definition follows ICH Q11 criteria, and the analytical release panel includes assay (HPLC area-%, ≥98.0%), specific rotation ([α]²⁰D = +36.0° ± 2.0° c=1, CHCl₃), and residual palladium below 10 ppm if hydrogenolytic deprotection has been employed. Downstream, the resulting amide is further elaborated into pyrrolidine-containing lead compounds—exemplified by CCR5 antagonists and JAK inhibitors—where the chiral aminomethylpyrrolidine moiety contributes to receptor-binding affinity, as confirmed by X-ray co-crystal structures. During scale-up, a process bottleneck arises from the need to dry the hygroscopic hydrochloride salt to constant weight before coupling; moisture content above 1.5% w/w leads to incomplete conversion and a rise in the des-chloro impurity to >0.5 area%.

Disruption of Pheromone-Mediated Mating Signals via Enantiopure Pyrrolidine Precursors

Synthesis of certain lepidopteran sex pheromones, such as (5R)-dec-1-en-6-yl acetate, can utilise (R)-2-(aminomethyl)pyrrolidine as a chiral derivatising agent or building block to introduce stereogenic centres via diastereoselective alkylation. Although published data for this specific configuration in pheromone production is limited, the protected pyrrolidine scaffold offers a convenient source of a primary amine for amide or sulfonamide linkage to long-chain alkenyl precursors. A representative procedure charges 0.8–0.9 eq of the deprotected amine hydrochloride with respect to a fatty acid activated ester in dichloromethane, keeping the amine sub-stoichiometric to minimise racemic by-products in the subsequent nucleophilic substitution. The coupling is conducted in a jacketed glass reactor at −10 °C to suppress aza-Michael side reactions, with conversion monitored by GC-FID (column: DB-5, 30 m × 0.25 mm). After aqueous work-up and concentration on a rotary evaporator at 35 °C bath temperature, the crude pheromone analogue is purified by silica gel chromatography (eluent: hexane/ethyl acetate 9:1) to afford >97% chemical purity. The final product is formulated into polymeric dispensers or microencapsulated suspensions for mating disruption trials. Regulatory oversight for the pheromone active substance, when registered as a biopesticide, requires compliance with EPA 40 CFR Part 158 or EU Regulation (EC) No 1107/2009 depending on the jurisdiction; the chiral intermediate provided to formulators is typically accompanied by a certificate of analysis citing enantiomeric excess determined by chiral GC (Cyclosil-B column, 30 m × 0.25 mm, 0.25 µm film) and residual solvent levels meeting USP <467> or Ph. Eur. 5.4 guidelines.

Alkylation of the secondary nitrogen in the deprotected pyrrolidine unit with 1.0 eq of 1-bromooctane at 70 °C in acetonitrile for 24 hours produces a quaternary ammonium bromide that, after ion exchange with lithium bis(trifluoromethanesulfonyl)imide, yields a chiral ionic liquid (CIL) exhibiting a glass transition temperature below −50 °C and a decomposition onset at 320 °C (TGA, N₂ atmosphere). The CIL is applied as a solvent-modifier in capillary electrophoresis for enantioseparation of non-steroidal anti-inflammatory drugs; a background electrolyte containing 20 mM sodium phosphate (pH 7.0) and 15 mM CIL achieves baseline resolution (Rs > 2.0) of ibuprofen enantiomers on a fused-silica capillary (50 µm i.d., 60 cm total length). Production of the CIL requires strict control of halide content: residual bromide is measured by ion-selective electrode and maintained below 0.5% w/w to prevent corrosion in electrochemical applications. Water content is reduced to < 200 ppm through azeotropic drying with toluene before use as a solvent for asymmetric Michael additions, where the CIL influences the diastereomeric ratio through solvent-ordering effects. The manufacturing process is governed by REACH Regulation (EC) 1907/2006, and the supplier provides an extended safety data sheet that includes the product’s water hazard class (WGK 2) and biodegradability screening result (< 20% in 28 days, OECD 301 F). The terminal product is a bespoke reaction medium sold in research quantities (5–100 g) to medicinal chemistry and catalysis laboratories; storage must be under argon at −20 °C to prevent gradual discolouration caused by trace moisture.

When the Pyrrolidine Scaffold Replaces Proline in Peptidomimetic Design

Incorporation of the 2-aminomethylpyrrolidine residue into a peptide backbone at the i+1 position of a β-turn mimic requires conversion of the intermediate to its Fmoc-protected analogue. The free amine is treated with Fmoc-OSu (1.1 eq) and sodium carbonate in dioxane/water (2:1) to give Fmoc-(R)-2-(aminomethyl)pyrrolidine-1-carboxylate, which is then loaded onto a Wang resin via a p-nitrophenyl ester linkage. Solid-phase peptide synthesis is performed on a CEM Liberty Blue microwave peptide synthesizer; the Fmoc-protected pyrrolidine building block is delivered at 3–5 eq relative to resin substitution, activated with 0.45 M HCTU and 2 M DIPEA in DMF, and coupled for 2 minutes at 75 °C under microwave irradiation (20 W). Deprotection of the Fmoc group uses 20% 4-methylpiperidine in DMF. A key process failure mode occurs when the pyrrolidine nitrogen remains unprotected during coupling, leading to intrachain cyclisation and truncation sequences detectable by LC-MS with mass shifts of −18 Da (loss of water). After final TFA cleavage (cocktail: TFA/triisopropylsilane/water 95:2.5:2.5, 2 h), the crude peptidomimetic is precipitated in cold diethyl ether and purified by preparative RP-HPLC (C18 column, 250 × 21.2 mm, 5 µm) to >95% purity. The resulting macrocyclic peptide or constrained linear peptide is evaluated as a potential protein–protein interaction inhibitor in biochemical assays. During pre-clinical development, control over genotoxic impurities—particularly activated Fmoc-OSu residuals—must comply with ICH M7 guidelines, with quantitation limits set at the threshold of toxicological concern (1.5 µg/day).

Catalytic Performance Cliffs at Water Contents Above 0.5 Equivalents in Cross-Aldol Additions

The free amine, generated by quantitative Boc deprotection and liberated in its neutral form, serves as a highly enantioselective organocatalyst for the direct aldol reaction between acetone and 4-nitrobenzaldehyde. A catalyst loading of 10 mol% in neat acetone (5.0 M with respect to aldehyde) at −10 °C delivers the (R)-aldol adduct with 92% ee and 85% isolated yield after 48 h. Addition of 0.5 eq of water relative to the catalyst increases the rate by a factor of 3.5 while preserving enantioselectivity; however, the water content must be absolutely controlled because crossing the 0.8 eq threshold triggers a catastrophic drop in ee to < 70%, attributed to the formation of an achiral enamine-water aggregate detected by ¹H DOSY NMR. Process monitoring employs a ReactIR probe to track the disappearance of the aldehyde carbonyl stretch at 1702 cm⁻¹, with an intake of aldehyde dosage controlled by a syringe pump over 6 hours to mitigate the exotherm. In a pilot run inside a 50 L glass-lined reactor, the catalyst solution in acetone is pre-cooled to −15 °C and the solid aldehyde is added in 10 portions at 30-minute intervals; failure to maintain internal temperature below −8 °C results in a decrease of ee by approximately 1.2% per °C rise. The chiral β-hydroxy ketone product is extracted into ethyl acetate, washed with 1 M HCl to remove the catalyst, and vacuum-distilled (boiling point 138 °C at 0.5 mbar) to polymer-grade purity. Safety assessment of the catalyst itself is conducted per ISO 11014:2009, and the SDS notes incompatibility with strong oxidising agents and chlorinated solvents, which can undergo quaternisation at elevated temperatures, releasing methyl chloride. The final aldol product serves as a building block for calcium-channel blockers and as a chiral intermediate for natural product total synthesis. Any residual amine catalyst in the product is quantified by UPLC-MS with a limit of 50 ppm to conform to ICH Q3C Class 3 solvent guidelines when the material enters a GMP supply chain.